🇺🇸 Ceftazidime-avibactam in United States

337 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 337

Most-reported reactions

1. Death — 99 reports (29.38%)
2. Off Label Use — 58 reports (17.21%)
3. Drug Ineffective — 42 reports (12.46%)
4. Pathogen Resistance — 41 reports (12.17%)
5. Treatment Failure — 19 reports (5.64%)
6. Acute Kidney Injury — 16 reports (4.75%)
7. Product Use Issue — 16 reports (4.75%)
8. Septic Shock — 16 reports (4.75%)
9. Drug Resistance — 15 reports (4.45%)
10. Sepsis — 15 reports (4.45%)

Source database →

Frequently asked questions

Is Ceftazidime-avibactam approved in United States?

Ceftazidime-avibactam does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Ceftazidime-avibactam in United States?

Qilu Pharmaceutical Co., Ltd. is the originator. The local marketing authorisation holder may differ — check the official source linked above.